Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages

  Sancisi, Valentina ^a   Borettini, Gloria ^a   Maramotti, Sally ^a   Ragazzi, Moira ^a   Tamagnini, Ione ^a   Nicoli, Davide ^a   Piana, Simonetta ^a   Ciarrocchi, Alessia ^a  

^a Santa Maria Nuova Istituto di Ricovero e Cura A Carattere Scientifico Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF DIFFERENTIATION 1; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; RUNT RELATED TRANSCRIPTION FACTOR 2 GENE; THYROID PAPILLARY CARCINOMA; TUMOR CELL;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; CELL MOVEMENT; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; PHENOTYPE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84867239494     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1903     Document Type: Article

References (41)

1. Davies L, Welch HG 2010 Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg 136:440-444
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142
3. Nixon JI, Whitcher M, Palmer FL, Shaha AR, Shah JP, Patel S, Ganly I 14 May 2012 The impact of distant metastases at presentation on prognosis in patients differentiated carcinoma of the thyroid gland. Thyroidthy.2011-0535
4. Ciarrocchi A, Piana S, Valcavi R, Gardini G, Casali B 2011 Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells. European Journal of Cancer 47:934-945
5. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747-754 (Pubitemid 27516177)
6. Ruzinova MB, Benezra R 2003 Id proteins in development, cell cycle and cancer. Trends Cell Biol 13:410-418 (Pubitemid 36897645)
7. Lin GL, Hankenson KD 2011 Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem 112:3491-3501
8. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian JB, Stein GS, Gerstenfeld LC 2003 Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63:2631-2637 (Pubitemid 36605206)
9. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB 2005 The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591 (Pubitemid 41369178)
10. Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, Lian JB, Stein GS 2009 Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 69:6807-6814
11. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB 2010 Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811-821
12. van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, Lian JB, van Wijnen AJ, Stein JL, Stein GS 2010 The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGF- in prostate cancer cells. J Cell Biochem 109:828-837
13. Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR 2001 Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 106:97-106 (Pubitemid 32701077)
14. Selvamurugan N, Partridge NC 2000 Constitutive expression and regulation of collagenase-3 in human breast cancer cells. Mol Cell Biol Res Commun 3:218-223 (Pubitemid 30602027)
15. Inman CK, Shore P 2003 The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684-48689 (Pubitemid 41079508)
16. van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, Montecino MA, Galindo M, Lian JB, Stein JL, Stein GS, van Wijnen AJ 2012 Genomic promoter occupancy of Runt-related transcription factor RUNX2 in osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem 287:4503-4517
17. Ciarrocchi A, D'Angelo R, Cordiglieri C, Rispoli A, Santi S, Riccio M, Carone S, Mancia AL, Paci S, Cipollini E, Ambrosetti D, Melli M 2009 Tollip is a mediator of protein sumoylation. PLoS One 4:e4404
18. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C 1994 Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer 73:2206-2212 (Pubitemid 24107978)
19. Li YL, Xiao ZS 2007 Advances in Runx2 regulation and its isoforms. Med Hypotheses 68:169-175
20. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X 2002 Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22:7982-7992 (Pubitemid 35217306)
21. Endo T, Kobayashi T 2010 Runx2 deficiency in mice causes decreased thyroglobulin expression and hypothyroidism. Mol Endocrinol 24:1267-1273
22. Lee MH, Kim YJ, Yoon WJ, Kim JI, Kim BG, Hwang YS, Wozney JM, Chi XZ, Bae SC, Choi KY, Cho JY, Choi JY, Ryoo HM 2005 Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter. J Biol Chem 280:35579-35587 (Pubitemid 41532750)
23. Zhang Y, Hassan MQ, Xie RL, Hawse JR, Spelsberg TC, Montecino M, Stein JL, Lian JB, van Wijnen AJ, Stein GS 2009 Co-stimulation of the bone-related Runx2 P1 promoter in mesenchymal cells by SP1 and ETS transcription factors at polymorphic purine-rich DNA sequences (Y-repeats). J Biol Chem 284:3125-3135
24. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, Lian JB, Stein GS, Nanes MS 2002 Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2αA) is inhibited by tumor necrosis factor-α. J Biol Chem 277:2695-2701 (Pubitemid 34953297)
25. Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, Sasano H. Source 2010 Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 101:2670-2675
26. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS 2006 Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25:589-600 (Pubitemid 46071865)
27. Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, van Wijnen AJ, Salto-Tellez M 2009 Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 45:2239-2248
28. Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B 2010 Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 9:258
29. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, Westendorf JJ, Cheng L, Huang H 2011 FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 71:3257-3267
30. Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH, Gaudio E, Zanesi N, Jones KB, DeYoung B, Amir G, Gebhardt M, Warman M, Stein GS, Stein JL, Lian JB, Aqeilan RI 2010 Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increate tumorigenicity and aberrant Runx2 expression. Cancer Res 70:5577-5586
31. Leong DT, Lim J, Goh X, Pratap J, Pereira BP, Kwok HS, Nathan SS, Dobson JR, Lian JB, Ito Y, Voorhoeve PM, Stein GS, Salto-Tellez M,Cool SM, van Wijnen AJ 2010 Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res 12:R89
32. Endo T, Ohta K, Kobayashi T 2008 Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab 93:2409-2412 (Pubitemid 351831565)
33. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD 2007 Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 104:2803-2808 (Pubitemid 46327960)
34. Kessenbrock K, Plaks V, Werb Z 2010 Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67
35. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ 2003 Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114:33-45 (Pubitemid 36859839)
36. Itoh Y, Seiki M 2006 MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 206:1-8 (Pubitemid 41740711)
37. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M 2005 Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 90:5270-5278 (Pubitemid 41262285)
38. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ 2005 The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1 related anti-proliferative function in osteoblasts. J Biol Chem 280:20274-20285 (Pubitemid 40776725)
39. Teplyuk NM, Galindo M, Teplyuk VI, Pratap J, Young DW, Lapointe D, Javed A, Stein JL, Lian JB, Stein GS, van Wijnen AJ 2008 Runx2 regulates G protein-coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem 283:27585-27597
40. Baniwal SK, Little GH, Chimge NO, Frenkel B 2012 Runx2 controls a feed-forward loop between androgen and prolactin-induced proptein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 227:2276-2282
41. Pierce AD, Anglin IE, Vitolo MI, Mochin MT, Underwood KF, Goldblum SE, Kommineni S, Passaniti A 2012 Glucose-activated Runx2 phosphorylation promotes endothelial cell proliferation and angiogenic phenotype. J Cell Biochem 113:282-292